Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2016
Price : $35 *
At a glance
- Drugs CLR 1404 I-124 (Primary)
- Indications Glioblastoma
- Focus Diagnostic use
- Sponsors Cellectar Biosciences
- 08 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.